Peter Allotey, MD
Internal Medicine · Macon, GANPI 1164482808
Payments from drug & device makers
Across 248 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- AstraZeneca$606
- Novo Nordisk$506
- Sanofi-aventis U.S. LLC$439
- GSK$383
- Bayer$276
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,33598%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 47 | $1,063 |
| AstraZeneca | 23 | $606 |
| Novo Nordisk | 26 | $506 |
| Sanofi-aventis U.S. LLC | 12 | $439 |
| GSK | 19 | $383 |
| Bayer | 12 | $276 |
| Boehringer Ingelheim | 14 | $239 |
| Pfizer | 13 | $209 |
| Amgen | 9 | $148 |
| AbbVie | 8 | $138 |
| Johnson & Johnson | 7 | $134 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Medtronic(2 entities) | 2 | $115 |
| Novartis | 5 | $92 |
| Amarin Pharma, Inc. | 6 | $89 |
| Teva Pharmaceuticals USA, Inc. | 6 | $83 |
| Abbott | 4 | $80 |
| Exact Sciences | 3 | $66 |
| Abiomed | 2 | $54 |
| Lilly USA, LLC | 4 | $54 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Dexcom, Inc. | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Shield Therapeutics Inc | 2 | $41 |
| Atland Pharmaceuticals, LLC | 1 | $30 |
| Sanofi | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Medline Industries LP | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,430 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 127 | $149,919 |
| EliquisApixaban | 142 | $148,919 |
| MounjaroTirzepatide | 89 | $117,556 |
| JardianceEmpagliflozin | 76 | $106,324 |
| OzempicSemaglutide | 86 | $104,684 |
| FarxigaDapagliflozin Propanediol | 89 | $99,419 |
| LinzessLinaclotide | 94 | $96,668 |
| RybelsusSemaglutide | 46 | $86,199 |
| TradjentaLinagliptin | 72 | $63,036 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 182 | $55,281 |
| MyrbetriqMirabegron | 66 | $54,729 |
| EntrestoSacubitril/Valsartan | 44 | $48,133 |
| TrulicityDulaglutide | 29 | $47,133 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $45,267 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 202 | $44,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $506 | $190,884132 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $239 | $187,310171 claims |
| Lilly USA, LLCMounjaro, Trulicity | $54 | $164,690118 claims |
| PfizerEliquis | $209 | $148,919142 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $383 | $145,542435 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $606 | $122,622129 claims |
| AbbVieLinzess | $138 | $96,66894 claims |
| Astellas Pharma US IncMyrbetriq | $1,063 | $54,72966 claims |
| NovartisEntresto | $92 | $48,13344 claims |
| Johnson & JohnsonXarelto | $134 | $41,32731 claims |
| BayerKerendia | $276 | $19,92724 claims |
| Hikma Pharmaceuticals USAMitigare | $14 | $5,78020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Macon
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.